Sustained intravitreal delivery of connexin43 mimetic peptide by poly(d,l-lactide-co-glycolide) acid micro- and nanoparticles - Closing the gap in retinal ischaemia

- Cx43 MP was successfully loaded into PLGA nano- and microparticles.
- In vitro studies revealed a triphasic pattern with sustained release over months.
- Retinal ischaemia-reperfusion injury was used for in vivo studies.
- Intravitreally delivered Cx43 MP reduced Cx43 levels and promoted RGC survival.
- Nps-Cx43 MP showed the most promising results due to sustained peptide release.